136.18
-1.32(-0.96%)
Currency In USD
| Previous Close | 137.5 |
| Open | 136.33 |
| Day High | 137.59 |
| Day Low | 134.5 |
| 52-Week High | 161 |
| 52-Week Low | 111.09 |
| Volume | 48,123 |
| Average Volume | 432,238 |
| Market Cap | 8.14B |
| PE | -17.55 |
| EPS | -7.76 |
| Moving Average 50 Days | 130.36 |
| Moving Average 200 Days | 134.88 |
| Change | -1.32 |
If you invested $1000 in Ascendis Pharma A/S (ASND) since IPO date, it would be worth $7,232.08 as of December 30, 2024 at a share price of $136.18. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,001.54 as of December 30, 2024 at a share price of $136.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
GlobeNewswire Inc.
Dec 19, 2024 1:30 PM GMT
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
GlobeNewswire Inc.
Dec 16, 2024 1:30 PM GMT
- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin - Annualized height velocity was simila
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
GlobeNewswire Inc.
Dec 12, 2024 9:01 PM GMT
PDUFA goal date is July 27, 2025COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Appl